Latest Articles

Publication Date
All News Scientific
WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight - The Malaysian Reserve

WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight The Malaysian Reserve

Published: Nov. 12, 2025, 11:52 p.m.
Read Full Article
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors - The Manila Times

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors The Manila Times

Published: Oct. 24, 2025, 3:57 p.m.
Read Full Article
Genescience Pharmaceuticals divulges new 17β-HSD1 inhibitors - BioWorld MedTech

Genescience Pharmaceuticals divulges new 17β-HSD1 inhibitors BioWorld MedTech

Published: Sept. 29, 2025, 1 p.m.
Read Full Article
GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor - connectedtoindia.com

GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor connectedtoindia.com

Published: Aug. 26, 2025, 4:39 a.m.
Read Full Article
Synergistic effect of MDM2 inhibitors and radiotherapy in endometrial cancer - Nature

Synergistic effect of MDM2 inhibitors and radiotherapy in endometrial cancer Nature

Published: Aug. 18, 2025, 7:15 a.m.
Read Full Article
The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval - Labiotech.eu

The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval Labiotech.eu

Published: April 23, 2025, 1:01 p.m.
Read Full Article
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - BioMed Central

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central

Published: Feb. 28, 2025, 10:47 a.m.
Read Full Article
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - bmcwomenshealth.biomedcentral.com

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis bmcwomenshealth.biomedcentral.com

Published: Feb. 28, 2025, 10:47 a.m.
Read Full Article
(PDF) The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors - ResearchGate

(PDF) The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors ResearchGate

Published: Feb. 14, 2025, 3:13 a.m.
Read Full Article
Celmatix advances JNK inhibitor program for endometriosis - BioWorld Online

Celmatix advances JNK inhibitor program for endometriosis BioWorld Online

Published: Jan. 9, 2025, 2 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!